Literature DB >> 26387127

Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.

Nicola Logallo1,2, Christopher E Kvistad3,4, Lars Thomassen5,6.   

Abstract

Given that alteplase has been the only approved thrombolytic agent for acute ischemic stroke for almost two decades, there has been intense interest in more potent and safer agents over the last few years. Tenecteplase is a bioengineered mutation of alteplase with advantageous pharmacodynamics and pharmacokinetics. The superiority of tenecteplase over alteplase has been proven by in vitro and animal studies, and it was approved for use in myocardial infarction more than a decade ago. In patients with acute ischemic stroke, tenecteplase has shown promise in randomized phase II trials and the drug is currently being tested in four phase III clinical trials that will start delivering definite results in the near future: NOR-TEST (NCT01949948), TASTE (ACTRN12613000243718), TEMPO-2 (NCT02398656), and TALISMAN (NCT02180204).

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26387127     DOI： 10.1007/s40263-015-0280-9

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


  35 in total

1.  Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.

Authors:  F Van de Werf; C P Cannon; A Luyten; K Houbracken; C H McCabe; S Berioli; E Bluhmki; H Sarelin; F Wang-Clow; N L Fox; E Braunwald
Journal:  Am Heart J       Date:  1999-05       Impact factor: 4.749

2.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.

Authors:  C P Cannon; C M Gibson; C H McCabe; A A Adgey; M J Schweiger; R F Sequeira; G Grollier; R P Giugliano; M Frey; H S Mueller; R M Steingart; W D Weaver; F Van de Werf; E Braunwald
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

3.  A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.

Authors:  G R Thomas; H Thibodeaux; C J Errett; J M Badillo; B A Keyt; C J Refino; J A Zivin; W F Bennett
Journal:  Stroke       Date:  1994-10       Impact factor: 7.914

Review 4.  Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.

Authors:  Paul Tanswell; Nishit Modi; Dan Combs; Thierry Danays
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Authors:  Werner Hacke; Greg Albers; Yasir Al-Rawi; Julien Bogousslavsky; Antonio Davalos; Michael Eliasziw; Michael Fischer; Anthony Furlan; Markku Kaste; Kennedy R Lees; Mariola Soehngen; Steven Warach
Journal:  Stroke       Date:  2004-11-29       Impact factor: 7.914

6.  TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.

Authors:  C P Cannon; C H McCabe; C M Gibson; M Ghali; R F Sequeira; G R McKendall; J Breed; N B Modi; N L Fox; R P Tracy; T W Love; E Braunwald
Journal:  Circulation       Date:  1997-01-21       Impact factor: 29.690

7.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.

Authors:  Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan
Journal:  N Engl J Med       Date:  2015-04-17       Impact factor: 91.245

8.  Endovascular therapy for ischemic stroke with perfusion-imaging selection.

Authors:  Bruce C V Campbell; Peter J Mitchell; Timothy J Kleinig; Helen M Dewey; Leonid Churilov; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Thomas J Oxley; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Miriam Priglinger; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Monica Badve; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Geoffrey A Donnan; Stephen M Davis
Journal:  N Engl J Med       Date:  2015-02-11       Impact factor: 91.245

9.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

10.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321
View more
  6 in total

Review 1.  Time window and "tissue window": two approaches to assist decision-making in strokes.

Authors:  XuYing Xiang; Fei Cao
Journal:  J Neurol       Date:  2018-06-19       Impact factor: 4.849

Review 2.  Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials.

Authors:  Babikir Kheiri; Mohammed Osman; Ahmed Abdalla; Tarek Haykal; Sahar Ahmed; Mustafa Hassan; Ghassan Bachuwa; Mohammed Al Qasmi; Deepak L Bhatt
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

3.  Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

Authors:  Nicola Logallo; Christopher E Kvistad; Aliona Nacu; Lars Thomassen
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

4.  Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion.

Authors:  Klearchos Psychogios; Lina Palaiodimou; Aristeidis H Katsanos; Georgios Magoufis; Apostolos Safouris; Odysseas Kargiotis; Stavros Spiliopoulos; Ermioni Papageorgiou; Aikaterini Theodorou; Konstantinos Voumvourakis; Elias Broutzos; Elefterios Stamboulis; Georgios Tsivgoulis
Journal:  Ther Adv Neurol Disord       Date:  2021-01-12       Impact factor: 6.570

Review 5.  Early Experience With Tenecteplase at a Comprehensive Stroke Center.

Authors:  Spozhmy Panezai; Ilya Dubinsky; Sindhu Sahito; Nancy Gadallah; Laura Suhan; Siddhart Mehta; Jawad Kirmani
Journal:  Neurol Clin Pract       Date:  2021-12

6.  Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study.

Authors:  Shuya Li; Yuesong Pan; Ziran Wang; Zhigang Liang; Huisheng Chen; Dong Wang; Yi Sui; Xingquan Zhao; Yilong Wang; WanLiang Du; Huaguang Zheng; Yongjun Wang
Journal:  Stroke Vasc Neurol       Date:  2021-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.